Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OPK
OPKO HEALTH, INC.
NASDAQ
$1.48
▼ DOWN 1.33% (-0.02)

KEY STATISTICS

Market Cap$1.10 B
52w High$1.73
52w Low$0.98
Dividend Yield—
Frequency—
P/E-5.48
Volume2.41M
Shares Out.746.33M

COMPANY

LEADERSHIP

Phillip Frost
CHIEF EXECUTIVE
Phillip Frost

COMPENSATION 2026

Salary$960,000
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$14,000
Total$1,854,000

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 2, 1995
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
2,275

PRICE TARGET

Target High$4.00
Target Low$1.60
Target Median$3.00
Target Consensus$2.87

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$136.62M
NOV
4
WED

PRICE

$1.48 ▼ DOWN 1.33% (−$0.02)
$1.47$1.48$1.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.48

About OPKO Health, Inc.

https://www.opko.com ↗

OPKO Health is a global healthcare company offering diagnostics, pharmaceuticals, and related products, including laboratory testing, specialty drugs, and over-the-counter items across multiple countries.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT OPKO HEALTH, INC. IS KNOWN FOR

NGENLA™ (somatrogon-ghla)
NGENLA™ (somatrogon-ghla)

NGENLA™ is a once-weekly FDA-approved human growth hormone analog for pediatric growth failure, now available in over 40 countries through Pfizer, aiming to revolutionize treatment for growth hormone deficiency.

COMPETITORS

COMPETITOR
ASND COMPARE
LLY COMPARE
NVO COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Service$95.24M $71.09M ▼$72.19M ▲$74.55M ▲
Transfer of Intellectual Property and Other$18.75M $33.7M ▲$13.97M ▼$46.09M ▲
Product$37.68M $43.66M ▲$38.04M ▼$42.94M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$110.92M $94.05M ▼$83.5M ▼$88.81M ▲
IRELAND$12.08M $22.1M ▲$9.68M ▼$41.66M ▲
CHILE$14.36M $17.48M ▲$14.87M ▼$16.43M ▲
SPAIN$6.34M $7.22M ▲$8.05M ▲$8.45M ▲
MEXICO$6.74M $6.26M ▼$6.94M ▲$7.04M ▲
Other Countries$1.09M $1.17M ▲$1.15M ▼$1.19M ▲
ISRAEL$140K $170K ▲— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
103
LISTED HERE
19
RANKED BY POSITION SIZE
XSU.TO
0.02% · 10.3M
VTS.AX
0.00% · 9.8M
SCHA
0.01% · 2.0M
R2SC.L
0.02% · 867.3K
GSSC
0.06% · 468.6K
ONEQ
0.01% · 452.1K
ISRA
0.40% · 437.5K
PRFZ
0.02% · 394.9K
XRS2.F
0.02% · 357.0K
DFAC
0.00% · 303.8K
SILX
2.87% · 247.3K
RSSL
0.02% · 191.3K
GERM
2.46% · 153.4K
TILT
0.00% · 61.5K
URTY
0.01% · 16.4K
LOPX
1.16% · 5.0K
PQ
PQSV
0.11% · 3.9K
USFMDN.MX
0.00% · 1.9K
FVI
0.01% · 576

INSTITUTIONAL OWNERSHIP

SHARES OWNED
29.03%
HOLDERS
381
TOP 12 OF 381 · RANKED BY POSITION SIZE
Rubric Capital Management LP
47.8M sh · $74.08M
Vanguard Group Inc
37.5M sh · $58.18M
Blackrock, Inc.
37.0M sh · $55.47M
Blackrock Inc.
29.2M sh · $36.56M
Geode Capital Management, LLC
11.6M sh · $17.38M
Blackrock Fund Advisors
11.3M sh · $105.37M
State Street Corp
10.3M sh · $15.46M
Blackrock Institutional Trust Company, N.A.
9.5M sh · $88.32M
Goldman Sachs Group Inc
7.7M sh · $8.75M
Ubs Group AG
6.1M sh · $6.92M
Whitefort Capital Management, LP
4.9M sh · $7.59M
Charles Schwab Investment Management Inc
3.8M sh · $5.84M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
OFFICER: SR. VICE PRESIDENT, CFO
Logal Adam
Sale · 53.3K shares
2026-07-24
★
DIRECTOR, OFFICER: EXECUTIVE VP-ADMINISTRATION
Rubin Steven D
Sale · 53.3K shares
2026-07-24
★
DIRECTOR
UPPALURI SUBBARAO V
Purchase · 80.0K shares
2026-06-18
★
DIRECTOR
Yu Alice Lin-Tsing
Purchase · 30.0K shares
2026-06-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
MARKET PERFORM 1
HOLD 1
2 GRADES IN THE LAST 12 MONTHS
Barrington Research MARKET PERFORM Jefferies HOLD

SECTORS PEERS

PEERPRICE
DNTH$105.84COMPARE
NKTR$72.52COMPARE
XNCR$26.06COMPARE
PSNL$17.07COMPARE
TNDM$21.43COMPARE
SANA$3.93COMPARE
PCRX$25.76COMPARE
OCS$12.21COMPARE